Accelerate Diagnostics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Accelerate Diagnostics Inc (AXDX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Accelerate Diagnostics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 11M vs 31,426M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+1.7% annualized vs trailing 12 months), vs holding steady (+0.2%) for its tracked peer group.
- Growth: Accelerate Diagnostics Inc generated -7.0% revenue growth year over year in Q4 2024, vs 77.0% for its tracked competitors combined.
- Profitability: Its -340.5% net margin compares with 14.1% for the peer group.
- Peer revenue share: Accelerate Diagnostics Inc accounted for 0.0% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.08M compares with $0.43M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AXDX Sales vs. its Competitors, Q4 2024
Accelerate Diagnostics Inc reported revenue contraction of 6.97 % year on year in Q4 2024, below its competitors' combined revenue growth of 76.96 %.
With a net margin of -340.48 %, Accelerate Diagnostics Inc reported lower profitability than its competitors (14.08 %).
Accelerate Diagnostics Inc generated 0.04 % of the combined sales of its peer group, down from 0.07 % a year earlier.
Accelerate Diagnostics Inc vs. its Competitors, Q4 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Accelerate Diagnostics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Accelerate Diagnostics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Accelerate Diagnostics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Accelerate Diagnostics Inc's competitor groups requires a Commercial License.
For context: the Laboratory Analytical Instruments industry grew revenue 13.2% year over year, combined, vs -7.0% for Accelerate Diagnostics Inc. Accelerate Diagnostics Inc's share of combined industry revenue moved from 0.03% to 0.03%, a loss of 0.01 percentage points.
Accelerate Diagnostics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Accelerate Diagnostics Inc | - | Yes | Yes | No |
| Competitors combined (7) | ||||
| High-Confidence Competitors (5) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AXDX Stock Performance relative to its Competitors
AXDX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Hologic Inc | 282.9% | Outperformed |
| 2 | Reflect Scientific Inc | 282.9% | Outperformed |
| 3 | Danaher Corporation | 282.9% | Outperformed |
| 4 | Quidelortho Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Accelerate Diagnostics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Accelerate Diagnostics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Accelerate Diagnostics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Accelerate Diagnostics Inc | 0.79 | 11.07 |
| Danaher Corporation | 162,068.70 | 25,107.00 |
| Hologic Inc | 17,087.75 | 3,644.80 |
| Cue Health Inc | 4,141.45 | 70.94 |
| Quidelortho Corp | 881.75 | 2,674.20 |
| Talis Biomedical Corporation | 29.16 | 2.85 |
| SUBTOTAL | 184,214.75 | 31,520.26 |
Sign in to see all competitors of Accelerate Diagnostics Inc .
Sources: Accelerate Diagnostics Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Accelerate Diagnostics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Accelerate Diagnostics Inc's Competitors Named by the Company
Competitive relationships identified from Accelerate Diagnostics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| T2 Biosystems | Company report | 85% |
| Danaher | Company report | 85% |
| Q-Linea | Company report | 85% |
| Gradientech | Company report | 85% |
| Specific Diagnostics | Company report | 85% |
| bioMerieux | Company report | 85% |
| Quantamatrix | Company report | 85% |
| Lifescale | Company report | 85% |
| TREK | Company report | 85% |
| Becton, Dickinson and Company | Company report | 85% |
| OPGN | Company report | 85% |
| TREK Diagnostics Systems, Inc. | Company report | 85% |
| Thermo Fisher Scientific | Company report | 85% |
| Capforce Inc | Company report | 85% |
| Selux Diagnostics | Company report | 85% |
| Specific Technologies | Company report | 85% |
| Cue Health Inc | Company report | 85% |
| Hologic Inc | Company report | 85% |
| Talis Biomedical Corporation | Company report | 85% |
| Quidelortho Corp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Accelerate Diagnostics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Accelerate Diagnostics Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Accelerate Diagnostics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Danaher Corporation | Diagnostics 39.36 % |
| Hologic Inc | Diagnostics 51.18 % |
| Quidelortho Corp | North America 51.89 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Accelerate Diagnostics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Accelerate Diagnostics Inc | 1 | 82,619 | -373,470 |
| Danaher Corporation | 162,069 | 418,450 | 66,733 |
| Hologic Inc | 17,088 | 515,530 | 76,917 |
| Cue Health Inc | 4,141 | 886,700 | -4,668,300 |
| Quidelortho Corp | 882 | 411,415 | -161,292 |
| Talis Biomedical Corporation | 29 | 44,563 | -797,281 |
| PEERS TOTAL | 184,214 | 426,844 | 41,077 |
Sign in to see all peers for Accelerate Diagnostics Inc .
Accelerate Diagnostics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Danaher Corporation | North America 39.49 % |
| Hologic Inc | Non-US 30.23 % |
| Cue Health Inc | Non-US 0.85 % |
| Reflect Scientific Inc | International 58.90 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Accelerate Diagnostics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 28 companies in Accelerate Diagnostics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Accelerate Diagnostics Inc ranks #0 of 28 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,511, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Agilent Technologies inc | 48,951 | 21.85 % |
| 2 | Waters Corporation | 42,910 | 19.16 % |
| 3 | Illumina Inc | 40,169 | 17.93 % |
| 4 | Mettler toledo International Inc | 32,716 | 14.60 % |
| 5 | Revvity Inc | 1,234 | 5.2% |
| 6 | Avantor Inc | 1,234 | 5.2% |
| 7 | Bio rad Laboratories Inc | 1,234 | 5.2% |
| 8 | 10x Genomics Inc | 1,234 | 5.2% |
| 9 | Bruker Corporation | 1,234 | 5.2% |
| 10 | Alamar Biosciences Inc | 1,234 | 5.2% |
| 0 | Accelerate Diagnostics Inc | 1 | 0.00 % |
Market cap and industry share for the rest of Accelerate Diagnostics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-05-14.
Accelerate Diagnostics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Laboratory Analytical Instruments industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (50 companies). See the full Laboratory Analytical Instruments industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 24.42 % | 39.42 % (avg) | -15.0 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -16.27 % (avg) | - |
| Capital Intensity (Capex / Revenue) | - | 7.92 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Accelerate Diagnostics Inc's Valuation vs Competitive Position
Valuation multiples vs the Laboratory Analytical Instruments industry average (50 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Laboratory Analytical Instruments industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 32.7x | - |
| EV / EBITDA | - | 20.7x | - |
| P/B | -0.9x | 2.9x | -3.8x |
| Return on Equity | 121.18 % | industry aggregate | 122.31 % |
| Return on Invested Capital | 108.87 % | -10.27 % (avg) | 119.14 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Accelerate Diagnostics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 500.00 % | 81.34 % | 22.18 % | 20.09 % | 45.83 % | 8.23 % | -23.58 % | 13.61 % |
| Operating Margin | -1,485.20 % | -1,181.29 % | -783.38 % | -570.53 % | -439.50 % | - | - | - |
| Return on Invested Capital | -27.01 % | -31.95 % | -44.40 % | -111.16 % | -263.10 % | -178.53 % | 164.60 % | 108.87 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Accelerate Diagnostics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,511 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Accelerate Diagnostics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Accelerate Diagnostics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Accelerate Diagnostics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 122.3 points above the industry aggregate.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of tracked competitors (42.90 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Accelerate Diagnostics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Accelerate Diagnostics Inc | 0.73 | 1.15 | - |
| Danaher Corporation | - | 1.73 | 0.40 |
| Hologic Inc | 1.88 | 3.64 | 0.51 |
| Cue Health Inc | 2.20 | 3.54 | - |
| Quidelortho Corp | 0.14 | 1.51 | 1.82 |
| Talis Biomedical Corporation | 8.45 | 8.66 | - |
Sign in to see all peers for Accelerate Diagnostics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Accelerate Diagnostics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Accelerate Diagnostics Inc | Q4 2024 | -7.0 % | - |
| Danaher Corporation | Q2 2026 | +5.5 % | +56.8 % |
| Hologic Inc | Q4 2025 | +44.8 % | -10.9 % |
| Cue Health Inc | Q4 2023 | -87.2 % | - |
| Quidelortho Corp | Q2 2026 | +2.8 % | - |
| Talis Biomedical Corporation | Q2 2024 | - | - |
| PEERS TOTAL | +6.8 % | +83.1 % |
Sign in to see all peers for Accelerate Diagnostics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Accelerate Diagnostics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Accelerate Diagnostics Inc | Q4 2024 | -16.5 % | - |
| Danaher Corporation | Q2 2026 | +10.0 % | +8.5 % |
| Hologic Inc | Q4 2025 | -18.1 % | -54.3 % |
| Cue Health Inc | Q4 2023 | -60.6 % | -81.8 % |
| Quidelortho Corp | Q2 2026 | +5.6 % | -32.0 % |
| Talis Biomedical Corporation | Q2 2024 | - | - |
Sign in to see all peers for Accelerate Diagnostics Inc .
Accelerate Diagnostics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Accelerate Diagnostics Inc | - | - | - |
| Danaher Corporation | 4.72% | 5.44% | 7.66% |
| Hologic Inc | 6.12% | 7.26% | 11.01% |
| Cue Health Inc | - | - | - |
| Quidelortho Corp | - | - | - |
| Talis Biomedical Corporation | - | - | - |
Sign in to see all peers for Accelerate Diagnostics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Accelerate Diagnostics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Accelerate Diagnostics Inc | - | 0.07 |
| Danaher Corporation | 40.75 | 6.46 |
| Hologic Inc | 31.65 | 4.69 |
| Cue Health Inc | - | 58.38 |
| Quidelortho Corp | - | 0.33 |
| Talis Biomedical Corporation | - | 10.22 |
| PEERS AVERAGE | 61.77 | 5.84 |
Sign in to see all peers for Accelerate Diagnostics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.